恐懼症治療市場－全球產業規模、佔有率、趨勢、機會和預測，按恐懼症類型、治療方法、最終用戶、地區和競爭格局分類，2020-2030年預測

2024年全球恐懼症治療市場規模為19.2億美元，預計2030年將以5.78%的複合年成長率成長至26.9億美元。恐懼症治療涵蓋多種旨在緩解對特定物體、情境或活動的強烈且非理性恐懼的治療介入。這些治療主要包括心理療法，例如認知行為療法和暴露療法，並經常輔以藥物療法，包括抗焦慮藥物和抗憂鬱藥，以控制相關症狀。市場成長的主要促進因素包括：全球對精神健康問題的認知不斷提高和污名化現象的消除；對實證心理介入措施的需求日益成長；以及治療模式的不斷進步，包括基於數位和虛擬實境的解決方案。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球恐懼症治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依恐懼症類型分類（動物恐懼症、懼高症、廣場恐懼症、幽閉恐懼症、社交恐懼症、其他）
  • 依治療方法（療法、藥物）
  • 按最終使用者（醫院、精神科診所、恐懼症治療中心、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美恐懼症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲恐懼症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區恐懼症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲恐懼症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美恐懼症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球恐懼症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Sanofi SA
• Cambrex Corporation
• Teva Pharmaceutical Industries Ltd
• Midas Pharma GmbH
• Harman Finochem Ltd
• Pfizer Inc.
• AstraZeneca, Plc.
• Eli Lilly and Company
• Lupin Limited
• GlaxoSmithKline plc

第16章：策略建議

第17章調查會社について,免責事項

The Global Phobia Treatment Market , valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 5.78% to reach USD 2.69 Billion by 2030. Phobia treatment encompasses a variety of therapeutic interventions designed to alleviate intense and irrational fears of specific objects, situations, or activities. These treatments primarily involve psychotherapy, such as cognitive-behavioral therapy and exposure therapy, frequently complemented by pharmacotherapy, including anxiolytics and antidepressants, to manage associated symptoms. The market's growth is largely supported by increasing global awareness and destigmatization of mental health conditions, a rising demand for evidence-based psychological interventions, and ongoing advancements in therapeutic modalities, including digital and virtual reality-based solutions.

Key Market Drivers

The increasing prevalence of phobia-related disorders and growing awareness of mental health are pivotal in driving the global phobia treatment market. As a subset of anxiety disorders, the widespread incidence of these conditions creates substantial demand for therapeutic interventions. According to the World Health Organization, in its September 2025 "Anxiety disorders" fact sheet, 359 million people globally were affected by anxiety disorders in 2021, signifying a pervasive need for effective treatment. This underlying requirement is actively met as growing awareness and acceptance encourage individuals to seek professional help. Proactive governmental and healthcare initiatives further bolster this shift away from stigmatization.

Key Market Challenges

The persistent limited access to specialized mental health professionals globally constitutes a significant challenge for the expansion of the phobia treatment market. Despite the high prevalence of phobias and increasing mental health awareness, a substantial portion of the affected population struggles to receive appropriate care. This access barrier directly curtails the availability and delivery of effective therapeutic interventions, such as cognitive-behavioral therapy and exposure therapy. According to the World Health Organization's Mental Health Atlas 2024, the global median for mental health workers was 13 per 100,000 people, but this figure demonstrates extreme disparities, with lower-income countries reporting as few as 1.1 specialized mental health workers per 100,000 people compared to 67.2 in high-income countries. Such a pronounced shortage of trained professionals, particularly in underserved regions, means that many individuals seeking treatment cannot initiate or sustain their care, thereby restricting the market's potential for growth and the overall reach of phobia treatment services.

Key Market Trends

The integration of Virtual Reality (VR) exposure therapy represents a transformative trend in the global phobia treatment market. This innovative approach provides immersive and controllable environments, allowing patients to safely and repeatedly confront their specific phobias, thereby overcoming the practical and logistical challenges associated with traditional in-vivo exposure. The growing clinical acceptance of this modality is evident, with the American Psychiatric Association, in its October 2023 article "Transforming Mental Health Care: The Rise of VR/AR Applications in Psychiatry," highlighting VR's broad applications in psychiatry, including its common use in immersive exposure therapy for phobias. This underscores the increasing relevance and endorsement of VR within the professional mental healthcare community.

Key Market Players

• Sanofi S.A
• Cambrex Corporation
• Teva Pharmaceutical Industries Ltd
• Midas Pharma GmbH
• Harman Finochem Ltd
• Pfizer Inc.
• AstraZeneca, Plc.
• Eli Lilly and Company
• Lupin Limited
• GlaxoSmithKline plc

Report Scope:

In this report, the Global Phobia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Phobia Treatment Market , By Type of Phobia:

• Zoophobia
• Acrophobia
• Agoraphobia
• Claustrophobia
• Social Phobia
• Others

Phobia Treatment Market , By Treatment:

• Therapy
• Medication

Phobia Treatment Market , By End User:

• Hospitals
• Psychiatry Clinics
• Phobia Treatment Centers
• Others

Phobia Treatment Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Phobia Treatment Market .

Available Customizations:

Global Phobia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Phobia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Phobia (Zoophobia, Acrophobia, Agoraphobia, Claustrophobia, Social Phobia, Others)
  • 5.2.2. By Treatment (Therapy, Medication)
  • 5.2.3. By End User (Hospitals, Psychiatry Clinics, Phobia Treatment Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Phobia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Phobia
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Phobia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Phobia
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Phobia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Phobia
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Phobia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Phobia
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User

7. Europe Phobia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Phobia
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Phobia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Phobia
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. France Phobia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Phobia
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Phobia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Phobia
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Phobia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Phobia
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Phobia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Phobia
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End User

8. Asia Pacific Phobia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Phobia
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Phobia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Phobia
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. India Phobia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Phobia
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Phobia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Phobia
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Phobia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Phobia
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Phobia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Phobia
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End User

9. Middle East & Africa Phobia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Phobia
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Phobia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Phobia
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Phobia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Phobia
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Phobia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Phobia
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. South America Phobia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Phobia
  • 10.2.2. By Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Phobia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Phobia
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Phobia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Phobia
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Phobia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Phobia
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Phobia Treatment Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cambrex Corporation
• 15.3. Teva Pharmaceutical Industries Ltd
• 15.4. Midas Pharma GmbH
• 15.5. Harman Finochem Ltd
• 15.6. Pfizer Inc.
• 15.7. AstraZeneca, Plc.
• 15.8. Eli Lilly and Company
• 15.9. Lupin Limited
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer